Email Us Here

Brian Baldari's Resilient Performance Group Names the Landing Gap in Record Cross-Border Biotech Deals

Brian Baldari, Pharm.D., MBA, names the Landing Gap, the commercial exposure created when an asset developed under one regulatory and payer system must launch under another. Record licensing volume is being priced almost entirely on the science.